A groundbreaking study conducted by researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has unveiled critical insights into how Alzheimer’s disease manifests differently across diverse racial and ethnic populations. This research challenges existing paradigms largely based on studies of non-Hispanic white individuals, highlighting the necessity for more inclusive and representative investigations in the quest to understand Alzheimer’s disease pathology and improve diagnostic precision.
The focus of this comprehensive investigation was the accumulation of tau, a protein closely linked with Alzheimer’s disease progression. The study utilized state-of-the-art positron emission tomography (PET) imaging with a newly developed tau tracer to detect abnormal tau protein tangles in the brains of over 1,500 cognitively normal and mildly impaired older adults. Notably, this cohort was racially and ethnically diverse, encompassing Black, Hispanic, and non-Hispanic white participants, which allowed for a robust analysis of the influence of ethnoracial identity on Alzheimer’s biomarkers.
Results indicated that Black and Hispanic individuals exhibited significantly higher tau burden in key memory-associated regions of the medial temporal lobe compared to non-Hispanic white participants, even in the absence of overt amyloid plaque buildup, which is traditionally considered the hallmark initiating event in Alzheimer’s pathology. This dissociation between amyloid and tau pathology among different groups disrupts the conventionally understood sequence of biomarker development and suggests alternative disease trajectories may be operative in diverse populations.
Furthermore, the relationship between biological markers and cognitive performance revealed complex interactions. While elevated tau correlated with impaired memory across the cohort, the interplay between amyloid plaque levels and memory decline was only evident in non-Hispanic white and Hispanic groups. Remarkably, in Black participants, amyloid levels did not strengthen the association between tau pathology and memory deficits. This finding implies that other, perhaps non-neuropathological, factors might be more influential in cognitive deterioration within this population.
Experts propose that beyond amyloid and tau pathology, additional elements such as vascular health comorbidities, chronic stress exposure, social determinants of health, and other systemic conditions could be driving memory decline in Black adults. This multifactorial influence necessitates a multidisciplinary approach integrating neurobiology, epidemiology, and social sciences to address Alzheimer’s disease in a clinically meaningful way across all communities.
The research also identified potential technical limitations associated with the tau PET tracer used. The imaging agent occasionally produced signals emanating from adjacent brain regions, confounding the interpretation of tau accumulation patterns. This observation underscores the imperative for rigorous validation of neuroimaging tools in heterogeneous populations to ensure the biological accuracy and reliability of PET data, preventing misinterpretation that could misguide diagnostic or therapeutic decisions.
This study, emerging from the Health and Aging Brain Study–Health Disparities (HABS-HD), represents one of the most extensive neuroimaging efforts targeting Alzheimer’s-related brain changes in racially and ethnically diverse aging populations within the United States. The success of this endeavor owes much to the advanced imaging infrastructure at Stevens INI, which facilitated high-resolution PET imaging and comprehensive data analysis.
Principal investigators emphasize that these findings carry profound implications for precision medicine in Alzheimer’s disease. A one-size-fits-all biomarker framework may inadvertently overlook distinctive pathophysiological mechanisms encountered in different ethnoracial groups. Consequently, clinical trials, diagnostic criteria, and therapeutic strategies must be recalibrated to accommodate biological variability shaped by genetic background, environment, and socio-cultural influences.
Importantly, the data advocate for longitudinal follow-up to dissect how tau, amyloid, vascular function, genetics—including the presence of the APOEε4 allele—and social determinants coalesce over time to influence cognitive trajectories. Such prolonged observation will be instrumental in unraveling the intricate web of contributory factors and optimizing prevention and intervention approaches tailored to diverse populations.
Moreover, the study’s revelations about non-amyloid influences on cognitive decline in Black adults spotlights the pressing need to investigate comorbid conditions and life-course exposures that may exacerbate or mimic Alzheimer’s symptoms. This integrative understanding is critical to avoid misdiagnosis and to design effective treatments that address the broader health context of patients.
The research team strongly advocates for the expansion of neuroimaging studies to encompass a wider array of communities historically underrepresented in Alzheimer’s research. Achieving true equity in neuroscientific inquiry will not only improve diagnostic sensitivity but also enhance the validity and generalizability of scientific findings, ultimately benefiting global populations afflicted by dementia.
In conclusion, this landmark study redefines the landscape of Alzheimer’s disease research by illustrating the heterogeneity in biomarker expression across ethnoracial groups. It challenges entrenched paradigms and sets the stage for a new era in which Alzheimer’s pathology is understood through the lens of diversity. Future efforts must continue to unravel these complex biological and social interdependencies to pave the way for personalized, equitable diagnostic and therapeutic solutions.
Subject of Research: People
Article Title: The relationships between ethnoracial identity, Aβ positivity, APOEε4, and medial temporal lobe tau PET
News Publication Date: 4-Mar-2026
Web References:
References:
10.1002/alz.71226
Image Credits: USC/Stevens INI
Keywords: Alzheimer disease, Tau proteins, Amyloid hypothesis, Amyloidosis, Dementia, Human brain, Brain, Positron emission tomography
